Company intelligence
Alamar Biosciences, Inc.
Powering Precision Proteomics with unrivaled sensitivity and simplicity
About Alamar Biosciences, Inc.
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.
Verified activity
Signals from Alamar Biosciences, Inc.
2 published signals
Presence & Recognition
Alamar Biosciences, Inc. is hosting a webinar on 16 September featuring Caroline Chan and Katharina Stracke discussing the NULISAseq Neuro 220 Panel and the Neuro 220 Pilot Program for researchers in Australia and New Zealand.
Reported by Alamar Biosciences, Inc.
Research & Knowledge
Alamar Biosciences, Inc. published a Biomarker Edge blog by CSO Stephen Williams, MD, PhD, exploring why amyloid alone doesn’t tell the whole Alzheimer’s story and how direct measurement of eMTBR-Tau could help address a critical gap in blood-based Alzheimer’s research.
Reported by Alamar Biosciences, Inc.